How Does a GLP-1 Work? The Actual Pharmacology Behind Zepbound and Wegovy

"It suppresses your appetite" is the version everyone repeats, and it isn't wrong — it's just the last step in a chain most explanations skip. The actual mechanism runs through a gut hormone system your body already had before semaglutide or tirzepatide existed. These drugs don't invent a new signal; they amplify and prolong one that's normally active for only a few minutes after you eat.

The hormone this is all built on: GLP-1

Glucagon-like peptide-1 is an incretin hormone your intestine releases naturally within minutes of eating, and it does three things almost simultaneously: it tells your pancreas to release insulin (but only when blood glucose is elevated), it slows the rate food leaves your stomach, and it signals directly to appetite-regulating neurons in your brain³⁴. The problem, pharmacologically, is that native GLP-1 is degraded by an enzyme called DPP-4 within one to two minutes of release — it's a signal built for a single meal, not an ongoing one. Semaglutide and tirzepatide are engineered to resist that breakdown; a small structural modification (a fatty-acid side chain that binds albumin in the blood) stretches the drug's active half-life from minutes to about a week, which is why both are dosed once weekly⁴. Same signal your body already makes — just running continuously instead of for a few minutes after a sandwich.

What it does in the brain: this is the appetite-suppression part

The GLP-1 receptor is expressed in the hypothalamus and brainstem, in regions — particularly the arcuate nucleus — that function as the brain's meal-planning center³⁴. Activating GLP-1 receptors there increases activity in neurons that promote satiety and dampens activity in neurons that drive hunger, which is the mechanistic basis for reduced food intake, fewer food cravings, and what patients commonly describe as "food noise" going quiet³. This is a real, receptor-level, central-nervous-system effect — not a side effect of feeling sick, and not willpower. It's also glucose-independent: the appetite effect operates whether or not your blood sugar is elevated at the time.

What it does in the gut: slower gastric emptying

Separately from the brain effect, GLP-1 receptor activation slows gastric emptying — food sits in your stomach longer before moving into the small intestine⁴. That's the physical basis for feeling full on a smaller meal, and it's also the direct mechanistic cause of the nausea, bloating, and reflux that show up early in treatment, especially during dose increases — see what the trials actually report on tirzepatide side effects and semaglutide side effects for the numbers. This is also why dosing starts low and titrates up slowly rather than starting at the effective maintenance dose: giving the gut time to adapt to slower emptying is the entire rationale for the step-up schedule, not caution for its own sake.

What it does to blood sugar: insulin and glucagon, but only when needed

GLP-1 receptor activation on pancreatic beta cells increases insulin secretion, and on alpha cells it suppresses glucagon (the hormone that raises blood sugar) — but both effects are glucose-dependent, meaning they scale up when blood glucose is high and largely turn off when it isn't³⁴. That glucose-dependence is the specific pharmacological reason GLP-1s carry a materially lower risk of causing hypoglycemia on their own compared to older insulin-secreting diabetes drugs — the insulin release has a built-in off-switch that older sulfonylureas don't have.

Where tirzepatide adds a second receptor

Semaglutide (Wegovy, Ozempic) activates the GLP-1 receptor alone — its own FDA label describes the mechanism as a GLP-1 receptor agonist that reduces food intake in part through effects on hypothalamic appetite regulation². Tirzepatide (Zepbound, Mounjaro) is a dual agonist — its FDA label describes it as activating both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor in a single molecule¹, a design confirmed in the drug's original discovery pharmacology⁵. GIP is a second incretin hormone with its own receptors in the hypothalamus and in fat tissue; in preclinical models, adding GIP receptor activity on top of GLP-1 improved insulin sensitivity and fat metabolism beyond what GLP-1 activation produced alone, which is the proposed biological basis for tirzepatide's larger average weight-loss effect in head-to-head data⁵. That's the mechanistic story behind the numbers in semaglutide vs. tirzepatide — it isn't just a stronger dose of the same thing, it's a second hormone pathway added to the first.

Does the mechanism itself explain a plateau?

Partly. Weight loss slows as body weight drops because energy requirements fall with body mass — a smaller body burns fewer calories at rest, which narrows the deficit the drug's appetite-suppressing effect is creating, independent of anything going wrong with the drug. See the GLP-1 weight-loss plateau for what the evidence says about that slowdown and what actually changes it.

What this means in practice

None of this is exotic biology — GLP-1 is a hormone your gut already makes, and these drugs work by keeping its signal switched on continuously instead of for the few minutes it normally lasts. That's a meaningfully different (and more reassuring) story than "it tricks your brain," and it's also why the side-effect profile, the titration schedule, and the size of the weight-loss effect all trace back to the same handful of receptors described above. The trial and mechanism literature behind this is indexed in our research library; see our methodology for how we evaluate evidence on this site. Not medical advice — see our medical disclaimer and talk to your prescriber about how this mechanism applies to your own treatment.